Shabtai Varsano1, David Segev2, David Shitrit3. 1. Department of Pulmonary Medicine, Meir Medical Center, Kfar Saba, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Asthma Care & Education Unit, Meir Medical Center, Kfar Saba, Israel. Electronic address: varsanos@bezeqint.net. 2. Clalit Health Services, Sharon-Shomron Medical District Headquarters, Tel Aviv, Israel. 3. Department of Pulmonary Medicine, Meir Medical Center, Kfar Saba, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: A large electronic database analysis was conducted in a community of 351,799 people, ages 20-70 years to determine the prevalence and clinical characteristics of severe asthma, according to 2014 international guidelines and healthcare utilization. METHODS: Severe asthmatics were grouped into controlled severe-asthma and uncontrolled severe-asthma and additional subgroups of uncontrolled severe asthma on the basis of medications dispensed. Non-asthmatic population at the same ages served as controls. RESULTS: A total of 19,991 (5.68%) were diagnosed as asthmatic, of which 4.65% had severe asthma. Of these, one-third was uncontrolled severe-asthma. Controlled severe-asthma group was similar to non-severe asthma and non-asthmatics in the rate of emergency room visits (21.5%, 22%, and 20%, respectively) and to all cause hospitalizations (7.4%, 7.4%, and 6.4%, respectively). Uncontrolled severe-asthmatics had significantly more hospitalizations (RR = 2.9) than controlled severe-asthmatics. Only 19.2% of uncontrolled-severe asthmatics had IgE testing and 3.6% were dispensed omalizumab. CONCLUSIONS: The prevalence of severe asthma is slightly less than 5% of all asthmatics. Controlling severe asthma is crucial to reducing healthcare utilization. A simple electronic database analysis, based on dispensed medications, can help healthcare providers identify subgroups of uncontrolled severe asthmatics that require focused efforts. CLINICAL TRIAL REGISTRATION: NCT01961258. Ethics Committee approval: 032/2013C.
BACKGROUND: A large electronic database analysis was conducted in a community of 351,799 people, ages 20-70 years to determine the prevalence and clinical characteristics of severe asthma, according to 2014 international guidelines and healthcare utilization. METHODS: Severe asthmatics were grouped into controlled severe-asthma and uncontrolled severe-asthma and additional subgroups of uncontrolled severe asthma on the basis of medications dispensed. Non-asthmatic population at the same ages served as controls. RESULTS: A total of 19,991 (5.68%) were diagnosed as asthmatic, of which 4.65% had severe asthma. Of these, one-third was uncontrolled severe-asthma. Controlled severe-asthma group was similar to non-severe asthma and non-asthmatics in the rate of emergency room visits (21.5%, 22%, and 20%, respectively) and to all cause hospitalizations (7.4%, 7.4%, and 6.4%, respectively). Uncontrolled severe-asthmatics had significantly more hospitalizations (RR = 2.9) than controlled severe-asthmatics. Only 19.2% of uncontrolled-severe asthmatics had IgE testing and 3.6% were dispensed omalizumab. CONCLUSIONS: The prevalence of severe asthma is slightly less than 5% of all asthmatics. Controlling severe asthma is crucial to reducing healthcare utilization. A simple electronic database analysis, based on dispensed medications, can help healthcare providers identify subgroups of uncontrolled severe asthmatics that require focused efforts. CLINICAL TRIAL REGISTRATION: NCT01961258. Ethics Committee approval: 032/2013C.
Authors: Sang Heon Kim; Ji Yong Moon; Jae Hyun Lee; Ga Young Ban; Sujeong Kim; Mi Ae Kim; Joo Hee Kim; Min Hye Kim; Chan Sun Park; So Young Park; Hyouk Soo Kwon; Jae Woo Kwon; Jae Woo Jung; Hye Ryun Kang; Jong Sook Park; Tae Bum Kim; Heung Woo Park; You Sook Cho; Kwang Ha Yoo; Yeon Mok Oh; Byung Jae Lee; An Soo Jang; Sang Heon Cho; Hae Sim Park; Choon Sik Park; Ho Joo Yoon Journal: Allergy Asthma Immunol Res Date: 2018-05 Impact factor: 5.764
Authors: Daniel P Henriksen; Uffe Bodtger; Kirsten Sidenius; Niels Maltbaek; Lars Pedersen; Hanne Madsen; Ehm A Andersson; Ole Norgaard; Louise Klokker Madsen; Bo L Chawes Journal: Eur Clin Respir J Date: 2018-11-07
Authors: A Vianello; M Caminati; M Andretta; A M Menti; S Tognella; G Senna; L Degli Esposti Journal: World Allergy Organ J Date: 2019-05-10 Impact factor: 4.084